SCHEMBL3028599

SCHEMBL3028599

CCn1nc(-c2ccsc2)c(C(C)=O)c(N)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.47
CSF1R P07333 1/20 0.47
FGFR1 P11362 1/20 0.47
FLT1 P17948 1/20 0.47
CSNK1A1 P48729 1/20 0.47
CDK8 P49336 1/20 0.47
GSK3A P49840 1/20 0.47
GSK3B P49841 1/20 0.47
CDK5 Q00535 1/20 0.47
PRKCQ Q04759 1/20 0.47
LRRK2 Q5S007 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
DYRK1B Q9Y463 1/20 0.47
PDE4B Q07343 2/20 0.43
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
BRD4 O60885 1/20 0.38
FLT4 P35916 1/20 0.38
MAPK8 P45983 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4056630 0.86 HSD17B10 (0.52) PDE4BCHEK2MEN1USP2MAPT
SCHEMBL3021825 0.84 KDR (0.53) KDRCSF1RFGFR1FLT1CSNK1A1
SCHEMBL3032899 0.82 CSF1R (0.69) KDRCSF1RFGFR1FLT1CSNK1A1
SCHEMBL3029722 0.81 CSF1R (0.53) KDRCSF1RFGFR1FLT1CSNK1A1
SCHEMBL4707624 0.78 KDR (0.50) KDRCSF1RFGFR1FLT1CSNK1A1
SCHEMBL3032453 0.78 CSF1R (0.50) KDRCSF1RFGFR1FLT1CSNK1A1
SCHEMBL3036246 0.78 ADORA1 (0.56) KDRCSF1RFGFR1FLT1CSNK1A1
SCHEMBL3040791 0.77 TBXAS1 (0.59) KDRCSF1RFGFR1FLT1CSNK1A1
SCHEMBL3036044 0.77 KDR (0.52) KDRCSF1RFGFR1FLT1CSNK1A1
SCHEMBL3029370 0.77 PDE4B (0.54) PDE4BADRA1DADRA1AADRA1BBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204241-A9 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES LABORATORIOS ALMIRALL, S. A. 2010-08-12 US disclosed
US-20090111819-A1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES LABORATORIOS ALMIRALL, S. A. 2009-04-30 US disclosed
US-7491722-B2 Pyridazin-3(2H)-one derivatives LABORATORIOS ALMIRALL S.A. (ES) 2009-02-17 US disclosed
EP-1575926-B1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES ALMIRALL LAB (ES) 2008-03-05 EP disclosed
US-20060173008-A1 New pyridazin-3(2h)-one derivatives LABORATORIOS ALMIRALL, S.A. (ES) 2006-08-03 US disclosed
EP-1575926-A1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES Almirall Prodesfarma, S.A. (ES) 2005-09-21 EP disclosed
WO-2004058729-A1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES ALMIRALL PRODESFARMA SA (ES) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111819-A1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES PDE4A, PDE3A, PDE3B KDR 603/4885CSF1R 2535/4885FGFR1 1861/4885
US-20060173008-A1 New pyridazin-3(2h)-one derivatives PDE3A, PDE4A, PDE3B KDR 679/4885CSF1R 2868/4885FGFR1 2317/4885
US-20100204241-A9 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES PDE4A, PDE3A, PDE3B KDR 603/4885CSF1R 2535/4885FGFR1 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.